Clinical Trial Update: PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update (completed) of PS-341 (bortezomib) in patients with refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts
• Myelodysplastic Syndrome with Excess Blasts in Transformation
• Myelodysplastic Syndromes

Drugs mentioned

• PS-341 (bortezomib) (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia | Phase 1 | Status: COMPLETED